Clinton C Mason
Overview
Explore the profile of Clinton C Mason including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
778
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Afify Z, Taj M, Orjuela-Grimm M, Srivatsa K, Miller T, Edington H, et al.
Cancer
. 2022 Dec;
129(5):780-789.
PMID: 36571557
Background: Pediatric Epstein-Barr virus-negative monomorphic post solid organ transplant lymphoproliferative disorder [EBV(-)M-PTLD] comprises approximately 10% of M-PTLD. No large multi-institutional pediatric-specific reports on treatment and outcome are available. Methods: A...
2.
Gonzalez M, Olivas I, Bencomo-Alvarez A, Rubio A, Barreto-Vargas C, Lopez J, et al.
Clin Transl Med
. 2022 Dec;
12(12):e1146.
PMID: 36536477
Tyrosine kinase inhibitors (TKIs) targeting BCR::ABL1 have turned chronic myeloid leukaemia (CML) from a fatal disease into a manageable condition for most patients. Despite improved survival, targeting drug-resistant leukaemia stem...
3.
Afify Z, Orjuela-Grimm M, Smith C, Dalal M, Ford J, Pillai P, et al.
Br J Haematol
. 2022 Dec;
200(3):297-305.
PMID: 36454546
Burkitt lymphoma arising in paediatric post-solid-organ transplantation-Burkitt lymphoma (PSOT-BL) is a clinically aggressive malignancy and a rare form of post-transplant lymphoproliferative disorder (PTLD). We evaluated 35 patients diagnosed with PSOT-BL...
4.
Claudiani S, Mason C, Milojkovic D, Bianchi A, Pellegrini C, Di Marco A, et al.
Cancers (Basel)
. 2021 Oct;
13(19).
PMID: 34638347
As the first FDA-approved tyrosine kinase inhibitor for treatment of patients with myelofibrosis (MF), ruxolitinib improves clinical symptoms but does not lead to eradication of the disease or significant reduction...
5.
Khalifa A, Mason C, Garvin J, Williams M, Del Fiol G, Jackson B, et al.
J Am Med Inform Assoc
. 2021 Sep;
28(12):2617-2625.
PMID: 34569596
Objective: In many cases, genetic testing labs provide their test reports as portable document format files or scanned images, which limits the availability of the contained information to advanced informatics...
6.
Khalifa A, Mason C, Garvin J, Williams M, Del Fiol G, Jackson B, et al.
Genet Med
. 2021 Aug;
23(11):2178-2185.
PMID: 34429527
Purpose: Genetic laboratory test reports can often be of limited computational utility to the receiving clinical information systems, such as clinical decision support systems. Many health-care interoperability (HC) standards aim...
7.
Mangum D, Meyer J, Mason C, Shams S, Maese L, Gardiner J, et al.
JAMA Oncol
. 2021 Aug;
7(10):1521-1528.
PMID: 34410295
Importance: Alterations in the IKZF1 gene drive B-cell acute lymphoblastic leukemia (B-ALL) but are not routinely used to stratify patients by risk because of inconsistent associations with outcomes. We describe...
8.
Khalifa A, Mason C, Garvin J, Williams M, Del Fiol G, Jackson B, et al.
Genet Med
. 2021 Jul;
23(11):2171-2177.
PMID: 34230635
Purpose: The availability of genetic test data within the electronic health record (EHR) is a pillar of the US vision for an interoperable health IT infrastructure and a learning health...
9.
Panza E, Ozenberger B, Straessler K, Barrott J, Li L, Wang Y, et al.
J Clin Invest
. 2021 Jun;
131(15).
PMID: 34156976
Clear cell sarcoma (CCS) is a deadly malignancy affecting adolescents and young adults. It is characterized by reciprocal translocations resulting in expression of the chimeric EWSR1-ATF1 or EWSR1-CREB1 fusion proteins,...
10.
Yan D, Franzini A, Pomicter A, Halverson B, Antelope O, Mason C, et al.
Blood Cancer Discov
. 2021 May;
2(3):266-287.
PMID: 34027418
We discovered that the survival and growth of many primary acute myeloid leukemia (AML) samples and cell lines, but not normal CD34+ cells, are dependent on SIRT5, a lysine deacylase...